AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 10448871 — intervention group
Group type: COMPARATOR
Intervention: Autoradiographic tumor rCMRGl
Number of subjects: 5
Study 10448871 — intervention group
Group type: EXPERIMENTAL
Intervention: K3 and kinetic rCMRGl of the recurring tumor
Number of subjects: 5
Study 10448871 — intervention group
Group type: COMPARATOR
Intervention: Postoperative follow-up
Number of subjects: 5
Study 7499664 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine gluconate pre-rinse
Number of subjects: 0
Study 7499664 — intervention group
Group type: COMPARATOR
Intervention: Essential oils pre-rinse
Number of subjects: 0
Study 7499664 — intervention group
Group type: COMPARATOR
Intervention: Water pre-rinse
Number of subjects: 0
Study 1430701 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide (0.4 mg at 8 AM and 8 PM)
Number of subjects: 17
Study 1430701 — intervention group
Group type: EXPERIMENTAL
Intervention: Bambuterol (20 mg at 8 PM)
Number of subjects: 17
Study 1430701 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 6744406 — intervention group
Group type: EXPERIMENTAL
Intervention: Brachial approach (antecubital cutdown procedure)
Number of subjects: 56
Study 6744406 — intervention group
Group type: COMPARATOR
Intervention: Femoral approach (percutaneous)
Number of subjects: 56
Study 30720538 — intervention group
Group type: EXPERIMENTAL
Intervention: Allogeneic mesenchymal stem/stromal cells (0.3, 1.0, or 3.0 million cells/kg body weight)
Number of subjects: 30
Study 30720538 — intervention group
Group type: COMPARATOR
Intervention: Control group (no mesenchymal stem/stromal cells)
Number of subjects: 30
Study 30189251 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical postoperative tobramycin-dexamethasone
Number of subjects: 70
Study 30189251 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 70
Study 26659113 — intervention group
Group type: EXPERIMENTAL
Intervention: Expressive writing (n=33)
Number of subjects: 67
Study 26659113 — intervention group
Group type: COMPARATOR
Intervention: Treatment-as-usual (control group, n=32)
Number of subjects: 67
Study 24781441 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine long-acting injection (405 mg/4 weeks)
Number of subjects: 524
Study 24781441 — intervention group
Group type: COMPARATOR
Intervention: Oral olanzapine (10 mg/d)
Number of subjects: 524
Study 22613240 — intervention group
Group type: EXPERIMENTAL
Intervention: Circuit class therapy with heart rate monitor feedback
Number of subjects: 53
Study 22613240 — intervention group
Group type: COMPARATOR
Intervention: Circuit class therapy without heart rate monitor feedback (Control)
Number of subjects: 53
Study 20053720 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal manipulation
Number of subjects: 210
Study 20053720 — intervention group
Group type: COMPARATOR
Intervention: Back school
Number of subjects: 210
Study 20053720 — intervention group
Group type: COMPARATOR
Intervention: Individual physiotherapy
Number of subjects: 210
Study 17349034 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral treatment for community acquired pneumonia
Number of subjects: 243
Study 17349034 — intervention group
Group type: COMPARATOR
Intervention: Intravenous (IV) treatment for community acquired pneumonia
Number of subjects: 243
Study 15549302 — intervention group
Group type: EXPERIMENTAL
Intervention: CH-SS-impregnated central venous catheters (CVCs) (n=51)
Number of subjects: 106
Study 15549302 — intervention group
Group type: COMPARATOR
Intervention: Standard uncoated triple-lumen CVC (Control) (n=55)
Number of subjects: 106
Study 11966418 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual, family, and community resources
Number of subjects: 261
Study 10202364 — intervention group
Group type: EXPERIMENTAL
Intervention: Allergen immunotherapy
Number of subjects: 0
Study 10202364 — intervention group
Group type: COMPARATOR
Intervention: Untreated allergic children
Number of subjects: 0
Study 10202364 — intervention group
Group type: COMPARATOR
Intervention: Healthy children
Number of subjects: 0
Study 7596624 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg imipramine
Number of subjects: 12
Study 2161692 — intervention group
Group type: EXPERIMENTAL
Intervention: hPTH 1‐38 (400 IU/day subcutaneous injection)
Number of subjects: 20
Study 2161692 — intervention group
Group type: EXPERIMENTAL
Intervention: hPTH 1‐38 (0.5 U/kg/h intravenous infusion)
Number of subjects: 20
Study 2161692 — intervention group
Group type: EXPERIMENTAL
Intervention: hPTH 1‐38 (intermittent treatment)
Number of subjects: 20
Study 2161692 — intervention group
Group type: EXPERIMENTAL
Intervention: hPTH 1‐38 therapy
Number of subjects: 20
Study 2161692 — intervention group
Group type: EXPERIMENTAL
Intervention: hPTH 1‐38 treatment
Number of subjects: 20
Study 2161692 — intervention group
Group type: COMPARATOR
Intervention: Calcitonin (100 U/day for 56 days)
Number of subjects: 20
Study 2161692 — intervention group
Group type: COMPARATOR
Intervention: No further treatment (control group)
Number of subjects: 20
Study 105096 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetracycline
Number of subjects: 25
Study 105096 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 31522133 — intervention group
Group type: EXPERIMENTAL
Intervention: Cigarette and e-cigarette dual-use
Number of subjects: 601
Study 31522133 — intervention group
Group type: COMPARATOR
Intervention: Cigarette-only smoking
Number of subjects: 601
Study 31522133 — intervention group
Group type: EXPERIMENTAL
Intervention: Cigarette and cannabis dual-use
Number of subjects: 601
Study 31522133 — intervention group
Group type: EXPERIMENTAL
Intervention: Cigarette and e-cigarette use
Number of subjects: 601
Study 31522133 — intervention group
Group type: EXPERIMENTAL
Intervention: Cigarette, e-cigarette, and cannabis poly-use
Number of subjects: 601
Study 27834959 — intervention group
Group type: EXPERIMENTAL
Intervention: Pterygium tissues
Number of subjects: 25
Study 27834959 — intervention group
Group type: COMPARATOR
Intervention: Normal conjunctival tissues
Number of subjects: 25
Study 24806469 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavior Change Techniques (BCTs) intervention
Number of subjects: 239
Study 23889806 — intervention group
Group type: EXPERIMENTAL
Intervention: Paricalcitol (2 μg/day)
Number of subjects: 26
Study 23889806 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 21827773 — intervention group
Group type: EXPERIMENTAL
Intervention: Gallic acid (GA) supplementation (12.8 mg/person/d) for three days
Number of subjects: 0
Study 21827773 — intervention group
Group type: EXPERIMENTAL
Intervention: Gallic acid (GA) in rats
Number of subjects: 0
Study 19800668 — intervention group
Group type: EXPERIMENTAL
Intervention: Dutasteride 0.5 mg
Number of subjects: 59
Study 19800668 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study 16954767 — intervention group
Group type: EXPERIMENTAL
Intervention: One-hour nursing rounds
Number of subjects: 27
Study 16954767 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-hour nursing rounds
Number of subjects: 27
Study 16954767 — intervention group
Group type: COMPARATOR
Intervention: Baseline data (no intervention)
Number of subjects: 27
Study 14709514 — intervention group
Group type: EXPERIMENTAL
Intervention: Different facemasks used for aerosol medication delivery
Number of subjects: 0
Study 11830774 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuroendoscopic operations (n = 10)
Number of subjects: 38
Study 11830774 — intervention group
Group type: COMPARATOR
Intervention: Conventional cystoperitoneal shunting operations (n = 28)
Number of subjects: 38
Study 9228352 — intervention group
Group type: EXPERIMENTAL
Intervention: Albuterol solution, 5 mg via nebulizer (Puritan‐Bennett Raindrop) impelled with oxygen at 8 L/min
Number of subjects: 27
Study 9228352 — intervention group
Group type: EXPERIMENTAL
Intervention: Albuterol, 400 microg via CFCMDI attached to a 145‐mL valved aerosol holding chamber (Aerochamber)
Number of subjects: 27
Study 9228352 — intervention group
Group type: EXPERIMENTAL
Intervention: Albuterol powder, 400 microg by Rotahaler
Number of subjects: 27
Study 8028563 — intervention group
Group type: EXPERIMENTAL
Intervention: embovin (10 mg/kg)
Number of subjects: 0
Study 8028563 — intervention group
Group type: COMPARATOR
Intervention: combatrin (10 mg/kg)
Number of subjects: 0
Study 2960867 — intervention group
Group type: EXPERIMENTAL
Intervention: General anesthesia
Number of subjects: 26
Study 2960867 — intervention group
Group type: COMPARATOR
Intervention: Spinal anesthesia
Number of subjects: 26
Study 29475446 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish meals
Number of subjects: 415
Study 29475446 — intervention group
Group type: COMPARATOR
Intervention: Meat meals
Number of subjects: 415
Study 29475446 — intervention group
Group type: EXPERIMENTAL
Intervention: n-3 LCPUFA supplements
Number of subjects: 415
Study 27456448 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive physiotherapy (three times daily)
Number of subjects: 92
Study 27456448 — intervention group
Group type: COMPARATOR
Intervention: Usual care physiotherapy (daily)
Number of subjects: 92
Study 25573904 — intervention group
Group type: EXPERIMENTAL
Intervention: Ritonavir powder formulation in water under fasting, moderate-fat or high-fat conditions
Number of subjects: 72
Study 25573904 — intervention group
Group type: EXPERIMENTAL
Intervention: Ritonavir powder formulation in chocolate milk or pudding under moderate-fat conditions
Number of subjects: 72
Study 25573904 — intervention group
Group type: COMPARATOR
Intervention: Ritonavir oral solution under moderate-fat conditions
Number of subjects: 72
Study 25573904 — intervention group
Group type: EXPERIMENTAL
Intervention: Ritonavir powder formulation in infant formula or apple sauce under moderate-fat conditions
Number of subjects: 72
Study 25573904 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-fat meals
Number of subjects: 72
Study 25573904 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat meals
Number of subjects: 72
Study 23964054 — intervention group
Group type: EXPERIMENTAL
Intervention: High-SFA (HS) diet
Number of subjects: 121
Study 23964054 — intervention group
Group type: EXPERIMENTAL
Intervention: High-MUFA (HM) diet
Number of subjects: 121
Study 23964054 — intervention group
Group type: EXPERIMENTAL
Intervention: High-carbohydrate (HC) diet
Number of subjects: 121
Study 20044759 — intervention group
Group type: EXPERIMENTAL
Intervention: Auditory discrimination training (ADT) in the same frequency of tinnitus pitch (SAME)
Number of subjects: 67
Study 20044759 — intervention group
Group type: EXPERIMENTAL
Intervention: Auditory discrimination training (ADT) in the frequency one-octave below tinnitus pitch (NONSAME)
Number of subjects: 67
Study 20044759 — intervention group
Group type: COMPARATOR
Intervention: Control group (waiting list group, WLG)
Number of subjects: 67
Study 18671882 — intervention group
Group type: EXPERIMENTAL
Intervention: Puzzle form of the Raven's Coloured Progressive Matrices (RCPM)
Number of subjects: 164
Study 18671882 — intervention group
Group type: COMPARATOR
Intervention: Book form of the Raven's Coloured Progressive Matrices (RCPM)
Number of subjects: 164
Study 16248249 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrative traditional and Western medicine (conventional Western medicine combined with Chinese compound recipe)
Number of subjects: 72
Study 16248249 — intervention group
Group type: COMPARATOR
Intervention: Conventional Western medicine alone
Number of subjects: 72
Study 14504325 — intervention group
Group type: EXPERIMENTAL
Intervention: Retinopathy
Number of subjects: 1684
Study 14504325 — intervention group
Group type: COMPARATOR
Intervention: Other retinal arteriolar characteristics (arteriovenous nicking, focal and generalized arteriolar narrowing)
Number of subjects: 1684
Study 9862837 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnetic resonance cholangiography (MRC)
Number of subjects: 70
Study 9862837 — intervention group
Group type: COMPARATOR
Intervention: Reference imaging methods (endoscopic retrograde cholangiography, endosonography, intraoperative cholangiography)
Number of subjects: 70
Study 9715310 — intervention group
Group type: EXPERIMENTAL
Intervention: Picrorhiza kurroa (Pk) root powder 375 mg three times a day for 2 weeks
Number of subjects: 33
Study 9715310 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study 2067712 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulbactam/Ampicillin (S/A)
Number of subjects: 65
Study 2067712 — intervention group
Group type: COMPARATOR
Intervention: Mezlocillin (M)
Number of subjects: 65
Study 6828609 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose of caffeine
Number of subjects: 96
Study 6828609 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium dose of caffeine
Number of subjects: 96
Study 6828609 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose of caffeine
Number of subjects: 96
Study 6828609 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 96
Study 30994935 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mM acetic acid in 0.1 M CaCl2 brines
Number of subjects: 6
Study 30994935 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochloric acid in 0.1 M CaCl2 brines
Number of subjects: 6
Study 30994935 — intervention group
Group type: COMPARATOR
Intervention: 0.1 M CaCl2 brines (without acidification)
Number of subjects: 6
Study 30994935 — intervention group
Group type: COMPARATOR
Intervention: 1 M NaCl brines
Number of subjects: 6
Study 28243598 — intervention group
Group type: COMPARATOR
Intervention: CT scans
Number of subjects: 46
Study 28243598 — intervention group
Group type: EXPERIMENTAL
Intervention: RSA double examinations
Number of subjects: 46
Study 25719441 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 40 mg
Number of subjects: 20
Study 25719441 — intervention group
Group type: COMPARATOR
Intervention: Rosuvastatin 40 mg alone
Number of subjects: 20
Study 25719441 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole with Rosuvastatin
Number of subjects: 20
Study 24615500 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus (EVE) 10 mg/day + Exemestane (EXE) 25 mg/day
Number of subjects: 724
Study 24615500 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PBO) + Exemestane (EXE) 25 mg/day
Number of subjects: 724
Study 22433267 — intervention group
Group type: EXPERIMENTAL
Intervention: Morning training group (MTG)
Number of subjects: 24
Study 22433267 — intervention group
Group type: EXPERIMENTAL
Intervention: Evening training group (ETG)
Number of subjects: 24
Study 22433267 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 24
Study 22433267 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (T0)
Number of subjects: 24
Study 22433267 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (T1)
Number of subjects: 24
Study 19670432 — intervention group
Group type: EXPERIMENTAL
Intervention: microS (MRX‐801) infusion over 90 minutes (Cohort 1, 1.4ml)
Number of subjects: 35
Study 19670432 — intervention group
Group type: EXPERIMENTAL
Intervention: microS (MRX‐801) infusion over 90 minutes (Cohort 2, 2.8ml)
Number of subjects: 35
Study 19670432 — intervention group
Group type: EXPERIMENTAL
Intervention: microS (MRX‐801) infusion over 90 minutes (Cohort 1)
Number of subjects: 35
Study 19670432 — intervention group
Group type: EXPERIMENTAL
Intervention: microS (MRX‐801) infusion over 90 minutes (Cohort 2)
Number of subjects: 35
Study 19670432 — intervention group
Group type: COMPARATOR
Intervention: tPA and brief TCD assessments (controls)
Number of subjects: 35
Study 18467522 — intervention group
Group type: EXPERIMENTAL
Intervention: Unblinded group (MR imaging results provided within 48 hours)
Number of subjects: 246
Study 18467522 — intervention group
Group type: COMPARATOR
Intervention: Blinded group (both patient and physician blinded to MR imaging results)
Number of subjects: 246
Study 18467522 — intervention group
Group type: COMPARATOR
Intervention: Blinded group
Number of subjects: 246
Study 18467522 — intervention group
Group type: EXPERIMENTAL
Intervention: Unblinded group
Number of subjects: 246
Study 16140896 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg riboflavin + 20 mg iron (n = 83)
Number of subjects: 333
Study 16140896 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg zinc (n = 83)
Number of subjects: 333
Study 16140896 — intervention group
Group type: COMPARATOR
Intervention: 1 mg riboflavin (control, n = 82)
Number of subjects: 333
Study 16140896 — intervention group
Group type: EXPERIMENTAL
Intervention: both (n = 85)
Number of subjects: 333
Study 12151469 — intervention group
Group type: EXPERIMENTAL
Intervention: iloprost (2.5 or 5.0 microg, six or nine times per day; median inhaled dose, 30 microg per day)
Number of subjects: 203
Study 12151469 — intervention group
Group type: EXPERIMENTAL
Intervention: iloprost
Number of subjects: 203
Study 12151469 — intervention group
Group type: EXPERIMENTAL
Intervention: iloprost (subgroup of primary pulmonary hypertension)
Number of subjects: 203
Study 12151469 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 203
Study 9935128 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyproterone acetate (CPA) 100 mg/d orally on days 1-10 of the menstrual cycle
Number of subjects: 39
Study 9935128 — intervention group
Group type: EXPERIMENTAL
Intervention: Flutamide 250 mg orally twice daily
Number of subjects: 39
Study 9935128 — intervention group
Group type: EXPERIMENTAL
Intervention: Triptorelin 3.75 mg IM every 28 days
Number of subjects: 39
Study 7486235 — intervention group
Group type: EXPERIMENTAL
Intervention: E5510 4 mg
Number of subjects: 227
Study 7486235 — intervention group
Group type: EXPERIMENTAL
Intervention: E5510 2 mg
Number of subjects: 227
Study 7486235 — intervention group
Group type: COMPARATOR
Intervention: Aspirin 324 mg
Number of subjects: 227
Study 2248075 — intervention group
Group type: EXPERIMENTAL
Intervention: Moclobemide (150-300 mg daily)
Number of subjects: 20
Study 2248075 — intervention group
Group type: COMPARATOR
Intervention: Tranylcypromine (15-30 mg daily)
Number of subjects: 20
Study 7377243 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal delivery
Number of subjects: 208
Study 7377243 — intervention group
Group type: COMPARATOR
Intervention: Elective cesarean section
Number of subjects: 208
Study 31365903 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical Activity (PA)
Number of subjects: 620
Study 27761984 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin 850 mg twice daily
Number of subjects: 12
Study 27761984 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 25399316 — intervention group
Group type: EXPERIMENTAL
Intervention: Mefenamic acid (250 mg capsules every 8 h)
Number of subjects: 122
Study 25399316 — intervention group
Group type: COMPARATOR
Intervention: Ginger (250 mg capsules every 6 h)
Number of subjects: 122
Study 24512486 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide 100 μg sc
Number of subjects: 10
Study 24512486 — intervention group
Group type: COMPARATOR
Intervention: Control (before administration of octreotide)
Number of subjects: 10
Study 20924555 — intervention group
Group type: EXPERIMENTAL
Intervention: Albumin
Number of subjects: 1218
Study 20924555 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 1218
Study 19346521 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan-based therapy
Number of subjects: 2049
Study 19346521 — intervention group
Group type: COMPARATOR
Intervention: Non-ARB-based pharmacotherapy
Number of subjects: 2049
Study 17277998 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (81-325 mg daily for at least a week)
Number of subjects: 100
Study 17277998 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel (75 mg daily for at least 3 days)
Number of subjects: 100
Study 15531660 — intervention group
Group type: EXPERIMENTAL
Intervention: PUFA-rich diet (P:S = 2.0)
Number of subjects: 16
Study 15531660 — intervention group
Group type: COMPARATOR
Intervention: SFA-rich diet (P:S = 0.25)
Number of subjects: 16
Study 11809123 — intervention group
Group type: EXPERIMENTAL
Intervention: nabumetone (1000 mg/day)
Number of subjects: 125
Study 11809123 — intervention group
Group type: COMPARATOR
Intervention: diclofenac sodium (75 mg/day)
Number of subjects: 125
Study 9662321 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified biophysical profile plus evaluation of the middle cerebral artery to umbilical artery systolic/diastolic ratio (Group 2)
Number of subjects: 665
Study 9662321 — intervention group
Group type: COMPARATOR
Intervention: Modified biophysical profile (Group 1)
Number of subjects: 665
Study 7819846 — intervention group
Group type: EXPERIMENTAL
Intervention: Midwives unit
Number of subjects: 2844
Study 3043571 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 ml prilocaine 1.5%
Number of subjects: 100
Study 3043571 — intervention group
Group type: COMPARATOR
Intervention: 40 ml bupivacaine 0.375%
Number of subjects: 100
Study 3043571 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 ml prilocaine 1% + 20 ml bupivacaine 0.5%
Number of subjects: 100
Study 3043571 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 ml prilocaine 2% + 20 ml bupivacaine 0.5%
Number of subjects: 100
Study 3043571 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 ml prilocaine 2% + 20 ml bupivacaine 0.375%
Number of subjects: 100
Study 31191103 — intervention group
Group type: EXPERIMENTAL
Intervention: Achilles tendon vibration (80 Hz) for 30 s
Number of subjects: 11
Study 31191103 — intervention group
Group type: EXPERIMENTAL
Intervention: Achilles tendon vibration (80 Hz) for 300 s
Number of subjects: 11
Study 31191103 — intervention group
Group type: COMPARATOR
Intervention: Passive control condition (300 s)
Number of subjects: 11
Study 29033547 — intervention group
Group type: EXPERIMENTAL
Intervention: Tablet formulation of tacrolimus
Number of subjects: 47
Study 24812287 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-biomarker disease activity (MBDA) score
Number of subjects: 235
Study 24812287 — intervention group
Group type: COMPARATOR
Intervention: Low and moderate MBDA scores
Number of subjects: 235
Study 24812287 — intervention group
Group type: COMPARATOR
Intervention: Low/moderate CRP, moderate DAS28-CRP, moderate DAS28-ESR
Number of subjects: 235
Study 24812287 — intervention group
Group type: EXPERIMENTAL
Intervention: MBDA score as a continuous variable
Number of subjects: 235
Study 24812287 — intervention group
Group type: EXPERIMENTAL
Intervention: MBDA score as a dichotomised variable (high vs low/moderate)
Number of subjects: 235
Study 23324897 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg daily
Number of subjects: 60
Study 23324897 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E 400 IU daily
Number of subjects: 60
Study 23324897 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60